Leerink Partnrs Issues Pessimistic Outlook for ITCI Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Analysts at Leerink Partnrs dropped their FY2027 EPS estimates for Intra-Cellular Therapies in a report released on Wednesday, October 30th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of $5.45 per share for the year, down from their previous estimate of $5.65. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ FY2028 earnings at $6.90 EPS.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.25) EPS.

Several other analysts have also issued reports on ITCI. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $68.00 to $92.00 in a research report on Friday, September 6th. JPMorgan Chase & Co. boosted their price target on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. UBS Group lowered their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average target price of $96.62.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $86.54 on Friday. The firm has a market cap of $9.17 billion, a price-to-earnings ratio of -99.47 and a beta of 0.97. Intra-Cellular Therapies has a 52 week low of $50.87 and a 52 week high of $88.00. The firm’s 50-day simple moving average is $75.18 and its two-hundred day simple moving average is $73.23.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Intra-Cellular Therapies by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock valued at $638,438,000 after purchasing an additional 131,679 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after purchasing an additional 525,000 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Intra-Cellular Therapies by 12.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after purchasing an additional 191,416 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock valued at $117,557,000 after purchasing an additional 661,052 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Intra-Cellular Therapies by 214.5% during the 2nd quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after buying an additional 606,358 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Sharon Mates sold 34,396 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $77,962,764.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 175,316 shares of company stock valued at $13,037,345 in the last quarter. Corporate insiders own 2.60% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.